Boutique webinar:
Multi-Omic Breakthroughs: Immune Monitoring for Precision Disease Detection
Introducing new approaches to immune monitoring
Helen McGuire, PhD, talks about how her team introduced a cutting-edge approach to immune monitoring that simplifies sample collection in multi-site clinical trials, particularly benefiting remote and underrepresented populations.
- Lung cancer immunotherapy response: A novel immune signature of lung cancer nonresponsiveness, developed using a 50-plus-marker CyTOF™ panel, can predict failure to respond to checkpoint therapies, offering a powerful tool for treatment decisions
- Plasma proteome analysis for disease detection: The SomaScan™ platform, which assesses over 11,000 proteins, is used to track disease progression and immune response in real time, opening up new possibilities for biomarker discovery
- Multi-omic data integration for enhanced predictability: Combining cellular and plasma-based immune data through advanced multi-omic integration can improve clinical outcome prediction
Watch to learn how you can apply these techniques to your own clinical trials and gain insights on how to improve disease detection, treatment effectiveness and overall trial outcomes.
Helen McGuire, PhD
Helen McGuire is a Senior Lecturer at the University of Sydney. Her interests are in emphasizing the use of technology to understand the role of the immune system in clinical applications of human disease. Following studies at UNSW and the Garvan Institute of Medical Research in Sydney, on an NHMRC ECR fellowship she undertook her postdoctoral training at Stanford University, and has subsequently pioneered the introduction of mass cytometry into the wider Australian research landscape.
Boutique webinar:
Multi-Omic Breakthroughs: Immune Monitoring for Precision Disease Detection
A presentation by Helen McGuire, PhD
More webinars
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.